<DOC>
	<DOCNO>NCT01655186</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled Phase 2 safety study assess effect bardoxolone methyl relative placebo body weight fat mass approximately 60 patient stage 4 Chronic Kidney Disease ( CKD ) Type 2 Diabetes Mellitus ( T2DM ) .</brief_summary>
	<brief_title>A Double-Blind , Randomized , Placebo-Controlled Study Evaluating Effects Bardoxolone Methyl Body Composition Patients With Stage 4 Chronic Kidney Disease Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Screening eGFR ≥ 15.0 &lt; 30.0 mL/min/1.73 m2 ; screen eGFR average eGFR value collect screening ; 2 . A history type 2 diabetes mellitus ; diagnosis must make ≥ 30 year age ; 3 . Male female patient least 30 year age ; 4 . Treatment angiotensin convert enzyme ( ACE ) inhibitor and/or angiotensin II receptor blocker ( ARB ) least 6 week prior Screening Visit A screening . The dosage ACE inhibitor and/or ARB must KDOQI goal dose ( Appendix 13.4 ) stable 2 week prior Screening Visit A screening ( i.e. , change dosage medication ) ; 5 . Mean systolic blood pressure ( SBP ) must ≤ 160 mmHg ≥ 105 mmHg mean diastolic blood pressure ( DBP ) must &lt; 90 mmHg screen visit A B ; 6 . Willing practice method birth control ( male partner childbearing potential female childbearing potential ) screening , take study drug least 30 day last dose study drug ingest ; 7 . Serum magnesium level must great equal 1.3 mEq/L Screening Visit B subsequent unscheduled visit screening ( serum magnesium level may reevaluate unscheduled visit ) ; 8 . Willing able give write informed consent study participation cooperate aspect protocol include tolerate closed MRI . Type 1 diabetes mellitus . If history diabetic ketoacidosis exists , fast Cpeptide level must confirm type 2 diabetes ; 2 . Known nondiabetic renal disease ( e.g. , polycystic kidney disease , focal segmental glomerulosclerosis ) [ nephrosclerosis superimpose diabetic kidney disease acceptable ] ; Ongoing clinical investigation evidence ( e.g. , unexplained hematuria red blood cell white blood cell cast ) suggest nondiabetic renal disease nephrosclerosis ; 4 . History renal transplant plan transplant live donor study ; 5 . Urine albumin/creatinine ratio ( UACR ) Screening Visit B great 3500 mg/g ; 6 . Hemoglobin A1c level &gt; 11.0 % screening ; 7 . Acute dialysis acute kidney injury within 12 week prior screen screen ; 8 . Clinical sign and/or symptom uremia expect need renal replacement therapy within 12 week follow randomization , assessed investigator ; 9 . Recently active cardiovascular disease define : Unstable angina pectoris within 12 week study randomization ; Myocardial infarction , coronary artery bypass graft surgery , percutaneous transluminal coronary angioplasty/stent within 12 week study randomization ; Cerebrovascular accident , include transient ischemic attack , within 12 week study randomization ; Current diagnosis Class III IV NYHA congestive heart failure ( Appendix 13.3 ) ; 10 . Clinical diagnosis severe obstructive valvular heart disease severe obstructive hypertrophic cardiomyopathy ; 11 . Atrioventricular block , 20 30 ; 12 . Implanted medical device would prevent obtain MRI ; 13 . Administration contrast agent may induce nephropathy within 30 day prior study randomization plan study ; 14 . Systemic immunosuppression 2 week , cumulatively , within 12 week prior randomization anticipate need immunosuppression study ; 15 . Total bilirubin , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) level great upper limit normal ( ULN ) alkaline phosphatase level great two time ULN ANY screen laboratory test result ; 16 . Female patient pregnant , intend become pregnant study , nursing ; 17 . BMI &lt; 18.5 kg/m2 ; 18 . Weight ≥ 300 pound ; 19 . Height &gt; 6 ' 3 '' ; 20 . Partial total amputation lower extremity prior randomization ; 21 . Known hypersensitivity component study drug ; 22 . Current history drug alcohol abuse , assess investigator ; 23 . Clinically significant infection require intravenous administration antibiotic hospitalization within 6 week prior Screening Visit A screening ; 24 . Hepatitis B surface antigen positive ; Diagnosis treatment malignancy past 5 year , exclude nonmelanoma skin cancer carcinoma situ cervix condition highly likely transform malignancy course study ; 26 . History bariatric surgery plan bariatric surgery course study ; 27 . A clinical condition , judgment investigator , could potentially pose health risk patient involve study ; 28 . Participation clinical study involve intervention within 30 day prior randomization , concurrent participation study , participation prior clinical study involve bardoxolone methyl form ; 29 . Unable communicate cooperate investigator due language problem , poor mental development , impaired cerebral function .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>